Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cola as a quick fix for esophageal blockages in cancer patients?

NCT ID NCT06652620

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether drinking cola can help relieve sudden food blockages in the esophagus for people with esophageal cancer. Fifty participants will be randomly assigned to drink cola or receive standard care, and researchers will check if the blockage clears within 24 hours. The goal is to find a simple, non-invasive way to manage this common and distressing problem.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cola (Coca-Cola or Pepsi-Cola)
What this could lead to
If it works, this could provide a simple, at-home remedy to quickly relieve food blockages in esophageal cancer patients, avoiding emergency procedures.
What could go wrong
This is a small, early-stage trial with only 50 participants, so results may not apply to everyone. Cola might not work for all blockages, and there is a risk of aspiration or worsening symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with primary esophageal lesions diagnosed by pathology, being able to consume at least a liquid diet normally before and diagnosed by a physician with acute esophageal impaction (acute esophageal impaction refers to the sudden occurrence of complete obstruction of eating within the past week) 2. Prior to enrollment, the patient did not consume carbonated beverages such as cola, or any other treatment for esophageal impaction. 3. Age ≥ 18 years old, Eastern Cooperative Oncology Group (ECOG) Performance Status score is 0-2 points. 4. The subjects voluntarily enrolled and obtained an informed consent form signed by the patient or their legal representative. Exclusion Criteria: 1. It is known that complete esophageal obstruction is caused by tumor progression. 2. Patients who have been diagnosed with or highly suspected of having esophageal fistula through endoscopy or imaging prior to enrollment. 3. Patients with nasogastric nutrition tube and esophageal stent implantation 4. Patients who have symptoms such as coughing and are unable to drink cola, or who are at serious risk of aspiration (Glasgow Coma Scale\<14 or previous history of aspiration). 5. Benign diseases such as gastroesophageal reflux, cardiac arrest, and congenital esophageal stenosis that can easily lead to foreign body impaction in the esophagus. 6. Patients with coagulation dysfunction, thrombocytopenia, or taking anticoagulant drugs that are medically considered contraindications for endoscopic examination and treatment. 7. According to the researchers' assessment, patients may not be able to cooperate with the examination and treatment, or there may be other factors that could force them to terminate the study midway, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the patients or the collection of experimental data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • First People's Hospital

    Jingdezhen, Jiangxi, China

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • Fudan University Shanghai Cancer Center Xiamen Hospital

    Xiamen, Fujian, China

  • The Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, 225001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.